Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery`-Reference-Cited by-同舟云学术

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery`

Published:2023-09-20 Issue: Volume:10 Page:38-43
ISSN:2331-4737
Container-title:Oncoscience
language:en
Short-container-title:Oncoscience

Author:

Gouda Mohamed A.¹,Janku Filip¹,Somaiah Neeta²,Hunt Kelly K.³,Yedururi Sireesha⁴,Subbiah Vivek¹⁵

Affiliation:

1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

2. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

3. Departments of Breast Surgical Oncology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

4. Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

5. Sarah Cannon Research Institute, Nashville, TN 37203, USA

Publisher

Impact Journals, LLC

Subject

Cancer Research,Oncology

Reference30 articles.

1. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016; 40:39–46. https://doi.org/10.1016/j.canep.2015.10.031. PMID:26618334

2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279:577–80. https://doi.org/10.1126/science.279.5350.577. PMID:9438854

3. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002; 160:1567–72. https://doi.org/10.1016/S0002-9440(10)61103-0. PMID:12000708

4. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299:708–10. https://doi.org/10.1126/science.1079666. PMID:12522257

5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21:4342–49. https://doi.org/10.1200/JCO.2003.04.190. PMID:14645423